Kyoto University

Other

Tokai University Educational System

Toyo Advanced Technologies Co., Ltd.

Japan Stent Technology Co., Ltd.

Tanaka Kikinzoku Kogyo K.k.

Kawasumi Laboratories. Inc.

Arkray, Inc.

Kyoto Prefectural Public University Corporation

Hiroo Iwata

Ikeuchi, Takeshi

Iwata, Hiroo

Mori, Kouji

Mitsudou, Kazuaki

Shuzo Yamashita

Akira Mochizuki

Ikuo Omura

Zhen Yu Jin

Yasushi Masahiro

Kunihiro Shima

Kenji Goto

Ryusuke Nakai

Tomonobu Kodama

Asaka Ueno

Masatoshi Watanabe

Kouji Mori

Hiroaki Nomiyama

Kazuaki Mitsudou

Yoshiharu Yoshikawa

Fumio Yamauchi

Shimon Sakaguchi

Kazunori Murakami

Masahide Hamaguchi

Ken Ikeuchi

Kunio Hirano

Shuzou Yamashita

Koichi Kato

Takeshi Ikeuchi

Rei Kuwabara

The present invention provides an alloy for medical use including an Au&#x2014;Pt alloy, in which the Au&#x2014;Pt alloy has a Pt concentration of 24 mass % or more and less than 34 mass % with the balance being Au, and has at least a material structure in which a Pt-rich phase having a Pt concentration higher than that of an &#x3b1;-phase is distributed in an &#x3b1;-phase matrix, the Pt-rich phase has a Pt concentration that is 1.2 to 3.8 times the Pt concentration of the &#x3b1;-phase, and the Pt-rich phase has an area ratio of 1 to 22% in any cross-section. This alloy is an artifact-free alloy material that exhibits excellent compatibility with a magnetic field environment such as an MRI and has magnetic susceptibility of &#xb1;4 ppm with respect to magnetic susceptibility of water.

Alloy for medical use, and method for producing same

A method for forming an immune-tolerant site, and a method for attracting immunosuppressive cells, comprising contacting an agent comprising SEK-1005 (Ser, 3-hydroxy-N-[2-hydroxy-1-oxo-2-tetrahydro-2-hydroxy-6-methyl-5-(2-methylpropyl)-2H-pyran-2-yl-propyl]-Leu-Pip(hexahydro-3-pyridazinecarbonyl)-N-hydroxy-Ala-N-methyl-Phe-Pip-rho-lactone) and/or fibroblast growth factor (FGF) with a site in the body tissue.

Method for forming an immune-tolerant site and method for attracting immunosuppressive cells

The present invention is an alloy for medical use including an Au&#x2014;Pt alloy, containing 34 to 36 mass % of Pt with the balance being Au, and having an &#x3b1;-phase single structure in which a ratio of a peak intensity (X) of a Pt (111) plane to a peak intensity (Y) of an Au (111) plane (X/Y) is 0.01 or less in an X-ray diffraction analysis. The alloy can be produced in such a manner that after the Au&#x2014;Pt alloy ingot is molten and cast, cold working and a heat treatment for homogenization are performed at least two times on the molten and cast alloy. The alloy of the present invention is an artifact-free material that exhibits excellent compatibility with a magnetic field environment such as an MRI and has magnetic susceptibility of &#xb1;4 ppm with respect to that of water.

Alloy for medical use and method of producing the same

A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.

Method of making a stent

A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.

Method of inhibiting vascular intimal hyperplasia using stent

A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.

Sustained drug-releasing stent

A stent having a generally tubular body formed of ring units formed of a plurality of cells each and expandable in the radial direction, wherein each ring unit is constituted of cells connected to one another above and below, arranged to surround the center line of the stent, the ring units are arranged in the axial direction of the stent, and are connected with connector portions, each connector portion is formed of curved portions each having an arch and a generally linear portion continued thereto, 3 to 8 cells are arranged in the axial direction per 10 mm of the length of the stent, and the ratio of the length of the cell in the axial direction and the length of the connector portion is determined such that on the basis that when the length of the cell is 100, that of the connector portionto, thereby securing flexibility and radial sustaining force.

Stent

The present invention relates to a method of introducing nucleic acids into cells by electroporation, comprising

Method of introducing nucelic acid

A stent () formed into a generally or substantially tubular body and expandable radially outward from inside of the tubular body, wherein cells () are connected vertically and so arranged as to surround the central axis (C) of the stent () and thereby to form annular units (), the annular units () are extended along the axis of the stent (), adjacent annular units () are connected at least at one portion by a connecting part (), each of the cells () has at least one bent portion, and the angle of the bent portion after expansion of the tubular body until the diameter becomes 2.5 mm is larger than 30&#xb0;. The stent ensures a high flexibility and radial support force, enhances the blood vessel expandability, and suppresses the foreshortening phenomenon and the flare phenomenon.

A projector,is provided for casting light toward the inside of a spherical screen,. A first reflecting mirror,is arranged inside the spherical screen,on the optical axis,of the projector,, and a second reflecting mirror,of a convex mirror on the optical axis,is arranged adjacent to a body tube,of the projector,. The light emitted from the projector,is cast onto the entire surface of the spherical screen,via the first and second reflecting mirrors,. Images with virtual presence can be projected onto the entire surface of the spherical screen by the simple structures using the single projector.

Full-surround spherical screen projection system and recording apparatus therefor

Growing community of inventors

Kyoto, Japan

Hiroo Iwata